Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
Bacteriostatic Water 101: Uses and Storage (Shelf-life after opening)
If you aren't planning pregnancy, reliable contraception is important during treatment
The National Institute for Health and Care Excellence (NICE) recommends the following monitoring approach for patients with hypertension who are starting weight-loss medications 3 : Establish a baseline blood pressure reading before starting treatment Check blood pressure at each dose escalation appointment Once on a stable dose, monitor blood pressure at least monthly for the first three months After three months, continue monitoring according to your usual hypertension care plan Many patients find home blood pressure monitoring helpful
